Adoptive therapy with T-cell receptor (TCR)–engineered T cells has shown promising results in the treatment of patients with tumors, and the number of TCRs amenable for clinical testing is expanding rapidly. Notably, adoptive therapy with T cells is challenged by treatment-related side effects, which calls for cautious selection of target antigens and TCRs that goes beyond their mere ability to induce high T-cell reactivity. Here, we propose a sequence of in vitro assays to improve selection of TCRs and exemplify risk assessments of on-target as well as off-target toxicities using TCRs directed against cancer germline antigens. The proposed panel of assays covers parameters considered key to safety, such as expression of target antigen in healthy tissues, determination of a TCR's recognition motif toward its cognate peptide, and a TCR's cross-reactivity toward noncognate peptides.

Additional Metadata
Persistent URL dx.doi.org/10.1158/1078-0432.CCR-17-1012, hdl.handle.net/1765/102451
Journal Clinical Cancer Research
Note no subscription
Citation
Kunert, A, Obenaus, M. (Matthias), Lamers, C.H.J, Blankenstein, T. (Thomas), & Debets, J.E.M.A. (2017). T-cell receptors for clinical therapy: In vitro assessment of toxicity risk. Clinical Cancer Research (Vol. 23, pp. 6012–6020). doi:10.1158/1078-0432.CCR-17-1012